Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD

Media formats available:

Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
AHA 2023
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
- Christian Ruff, MD
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
AHA 2023
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
- Ahmad Masri, MD
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
AHA 2023
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
- Michael Lincoff, MD
Novel RNAi therapeutic lowers blood pressure in patients with hypertension
Novel RNAi therapeutic lowers blood pressure in patients with hypertension
AHA 2023
Novel RNAi therapeutic lowers blood pressure in patients with hypertension
- George Bakris, MD

PACE-CME